Mayflower Financial Advisors’s CRISPR Therapeutics CRSP Stock Holding History

Mayflower Financial Advisors’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-13,558	Closed	-$79.2K	–	375
2024 Q2	$79.2K	Buy	13,558 +192	+1%	+$11.1K	0.01%	351
2024 Q1	$79.7K	Buy	13,366 +780	+6%	+$55.8K	0.01%	348
2023 Q4	$25.4K	Buy	12,586 +8	+0.1%	+$442	﹤0.01%	337
2023 Q3	$21.5K	Sell	12,578 -8	-0.1%	-$413	﹤0.01%	333
2023 Q2	$24.1K	Hold	12,586	–	–	﹤0.01%	349
2023 Q1	$21.8K	Sell	12,586 -37	-0.3%	-$1.8K	﹤0.01%	345
2022 Q4	$22.3K	Sell	12,623 -13	-0.1%	-$690	﹤0.01%	342
2022 Q3	$29K	Hold	12,636	–	–	﹤0.01%	322
2022 Q2	$28K	Sell	12,636 -342	-3%	-$20.1K	﹤0.01%	323
2022 Q1	$50K	Buy	+12,978	New	+$815K	0.01%	345

Other funds holding CRSP

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Mayflower Financial Advisors's CRSP Position: Q3 2024 in Review

Mayflower Financial Advisors sold out of CRISPR Therapeutics (CRSP) in Q3 2024, closing a stake of 13,558 shares — an estimated $79.2K sold.

Mayflower Financial Advisors first reported a position in CRSP in Q1 2022 and held it in 10 quarters. The position peaked at $79.7K in Q1 2024. 416 funds tracked by Wall St. Rank hold CRSP as of Q3 2024.

Mayflower Financial Advisors reported no remaining CRISPR Therapeutics position as of Q3 2024 after selling out during the quarter.
Mayflower Financial Advisors sold 13,558 CRISPR Therapeutics shares in Q3 2024, an estimated $79.2K.
Mayflower Financial Advisors first reported a position in CRISPR Therapeutics in Q1 2022 and held it in 10 quarters.
Mayflower Financial Advisors's CRISPR Therapeutics position peaked at $79.7K in Q1 2024.
416 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2024.

Based on Mayflower Financial Advisors's 13F filing for Q3 2024, filed 4 Nov 2024.